<code id='C57966E541'></code><style id='C57966E541'></style>
    • <acronym id='C57966E541'></acronym>
      <center id='C57966E541'><center id='C57966E541'><tfoot id='C57966E541'></tfoot></center><abbr id='C57966E541'><dir id='C57966E541'><tfoot id='C57966E541'></tfoot><noframes id='C57966E541'>

    • <optgroup id='C57966E541'><strike id='C57966E541'><sup id='C57966E541'></sup></strike><code id='C57966E541'></code></optgroup>
        1. <b id='C57966E541'><label id='C57966E541'><select id='C57966E541'><dt id='C57966E541'><span id='C57966E541'></span></dt></select></label></b><u id='C57966E541'></u>
          <i id='C57966E541'><strike id='C57966E541'><tt id='C57966E541'><pre id='C57966E541'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:explore    Page View:73288
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In